# Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer

> **NCT03878849** · PHASE2 · RECRUITING · sponsor: **Allarity Therapeutics** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Ovarian Cancer

## Interventions

- **DRUG:** 2X-121
- **DRUG:** 2X-121

## Key facts

- **NCT ID:** NCT03878849
- **Lead sponsor:** Allarity Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-04-15
- **Primary completion:** 2027-03
- **Final completion:** 2027-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-08-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03878849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03878849, "Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03878849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*